18 million people across Pacific coast, Andean highlands, Amazon basin, and Galápagos Islands ; a dollarized economy eliminating currency risk, dual research corridors in Guayaquil and Quito, growing tropical disease platform depth, and treatment-naïve patient pools across four ecologically distinct biomes.
Ecuador's research proposition is built on ecological diversity, currency stability, and strategic Andean position: the Americas' most compressed four-ecosystem research geography creates distinct disease and patient populations unavailable in any single comparator country; the US dollar eliminates currency risk entirely ; shared only with Panama among LATAM research markets; and Ecuador's position between Colombia and Peru in the Andean corridor creates natural multi-country network complementarity within the broader South American clinical development strategy.
ARCSA regulatory authority under MSP, incorporating WHO GCP and ICH GCP E6(R2) standards through Acuerdo Ministerial 5009 and subsequent resolutions; institutional CEI ethics committees at major research hospitals in Guayaquil, Quito, and Cuenca; MSP national ethics coordination; CAN (Andean Community) pharmaceutical harmonisation aligning Ecuador's regulatory framework with Colombia and Peru; improving ARCSA review timelines with growing international pharmaceutical company engagement in both Guayaquil and Quito corridors; SENESCYT national science funding supporting academic-commercial research partnerships.
The US Dollar is Ecuador's official currency since dollarization in 2000 ; one of only two South American research markets (alongside Panama) with zero foreign exchange risk for USD-denominated trial budgets; no sucre devaluation risk, no hedging required, no ARS/BRL/PEN currency management overhead; trial financial management equivalent to operating within the US dollar system; Ecuador's stable dollarized economy simplifies investigational product procurement, site payment logistics, and multi-year trial budgeting in ways that volatile-currency LATAM markets cannot match.
18M across four biomes creating distinct patient populations: dengue-hyperendemic Pacific coast cities (Guayaquil, Machala, Esmeraldas) for vaccine and antiviral trials; Andean highland communities with neurocysticercosis (one of the Americas' highest rates in some provinces), H. pylori-driven gastric cancer, and altitude pharmacokinetics; Amazonian indigenous populations for tropical NTD research and ancestral pharmacogenomics; Afro-Ecuadorian communities for Afro-Atlantic cardiovascular genetics; growing urban NCD (cardiovascular, diabetes, obesity) burden in Guayaquil and Quito; relatively treatment-naïve populations across all therapeutic areas due to historically lower trial activity than neighbouring Colombia or Peru.
Hospital Luis Vernaza (Guayaquil ; one of South America's most historically significant private-charitable hospitals); HECAM (Quito ; IESS flagship and Ecuador's most sophisticated public tertiary hospital); Hospital Eugenio Espejo (Quito national referral hospital); INSPI (WHO-partnered national public health research institute in Guayaquil); dual-corridor research infrastructure across Guayaquil and Quito providing geographic and demographic complementarity; Cuenca as a southern Andean third corridor; Clínica Kennedy (Guayaquil's most internationally connected private hospital); growing IQVIA, ICON, and Parexel presence in Guayaquil and Quito.
Guayaquil and Quito provide Ecuador's two parallel research corridors ; the coastal city and the highland capital ; each with distinct disease profiles, patient demographics, and hospital networks that together span Ecuador's four-biome research geography. Guayaquil dominates dengue, tropical disease, and cardiovascular research through Hospital Luis Vernaza, Hospital Teodoro Maldonado Carbo, and the IESS and MSP public hospital networks of the Pacific coast. Quito anchors highland research through HECAM and Hospital Eugenio Espejo, with altitude-related disease profiles, highland indigenous patient populations, and proximity to the neurocysticercosis-endemic central Andean provinces. Cuenca in the southern Andes provides a third corridor for the Andean population of Azuay and surrounding provinces.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Hospital Luis Vernaza | Guayaquil | One of South America's most historically significant hospitals ; operated since 1896 by the Junta de Beneficencia de Guayaquil, a private charitable foundation whose century-long hospital management tradition has created Ecuador's most institutionally stable major hospital outside the public sector ; and Guayaquil's most research-active institution; Phase I–IV across infectious disease, cardiovascular, oncology, gastroenterology, and internal medicine; Hospital Luis Vernaza's position as Ecuador's Pacific coast reference hospital for complex medicine and its long international reputation attract the most experienced Guayaquil investigator community and the most established pharmaceutical company relationships of any coastal Ecuadorian research institution; an essential first-call site for sponsors activating Guayaquil as the anchor of Ecuador Pacific corridor Phase II–III programs. |
| 02 | Hospital Teodoro Maldonado Carbo (IESS Guayaquil) | Guayaquil | IESS's flagship hospital on Ecuador's Pacific coast ; one of the largest and most sophisticated public hospitals in coastal South America ; covering IESS-insured formal sector workers and their families across Guayaquil and the Pacific coastal provinces; Phase II–IV across cardiovascular, oncology, metabolic disease, haematology, infectious disease, and internal medicine; Hospital Maldonado Carbo's massive patient volume ; managing hundreds of thousands of consultations across IESS's managed care infrastructure ; provides structured research access to Guayaquil's large mestizo and Afro-Ecuadorian working-class patient population through the formal insurance system; a critical site for sponsors requiring IESS patient-base access in Pacific coast Phase III designs where enrollment velocity is a primary driver of site selection. |
| 03 | Hospital Dr. Abel Gilbert Pontón | Guayaquil | A major MSP public referral hospital in Guayaquil ; one of the highest-volume public general hospitals on the Ecuadorian coast ; with Phase II–III research activity across infectious disease (dengue being the most clinically relevant given Guayaquil's hyperendemic status), oncology, cardiovascular, and internal medicine; Hospital Abel Gilbert Pontón's catchment from Guayaquil's lower-income urban and peri-urban districts provides research access to the large treatment-naïve patient populations most relevant to dengue, tropical disease, and metabolic disease programs; an important MSP complement to the IESS and private hospital research networks for sponsors requiring broad Guayaquil public patient coverage. |
| 04 | Clínica Kennedy | Guayaquil | Guayaquil's most internationally connected private hospital group ; operating multiple campuses across Guayaquil's residential and commercial districts ; and the most sophisticated private research institution in coastal Ecuador; Phase II–IV across oncology, cardiovascular, metabolic disease, and internal medicine; Clínica Kennedy's patient catchment from Guayaquil's professional and upper-middle-income population provides access to a private-pay mestizo and White Ecuadorian demographic whose health literacy and trial compliance rates are comparable to private research hospital populations in larger LATAM markets such as Bogotá or Lima; an important private hospital complement for sponsors designing Ecuador multi-site Phase III programs requiring patient coverage across the full Guayaquil socioeconomic spectrum. |
| 05 | Hospital Roberto Gilbert Elizalde (IESS) | Guayaquil | IESS's dedicated paediatric hospital in Guayaquil ; Ecuador's most important site for paediatric clinical research on the Pacific coast ; with Phase II–III activity across paediatric infectious disease (dengue in children, a critical population for dengue vaccine immunogenicity Phase II studies given the age-stratified immunological responses to dengue infection), respiratory disease, haematology, and paediatric oncology; Hospital Roberto Gilbert's paediatric infectious disease department has been active in dengue-related clinical programs reflecting Guayaquil's hyperendemic transmission environment, where paediatric dengue burden and age-specific seroprevalence patterns create important trial design opportunities for sponsors developing dengue vaccines requiring age-stratified immunogenicity data in a hyperendemic setting. |
| 06 | Hospital de Especialidades Carlos Andrade Marín (HECAM) | Quito | Ecuador's largest and most sophisticated public tertiary hospital ; IESS's flagship in the Andean highlands, located in Quito at 2,850m above sea level ; and the most research-active institution in highland Ecuador; Phase I–IV across cardiovascular, oncology, metabolic disease, haematology, neurology, and endocrinology; HECAM's extraordinary concentration of specialty medical expertise and diagnostic infrastructure ; reflecting its role as IESS's national reference hospital for complex medicine ; makes it the primary Phase II–III trial site for high-complexity cardiovascular, oncology, and haematological malignancy programs in highland Ecuador; its altitude-adapted Andean patient population provides unique pharmacokinetic research value for sponsors whose drugs require altitude-stratified data within a Latin American regulatory submission. |
| 07 | Hospital Eugenio Espejo | Quito | Ecuador's national MSP referral hospital ; the Ministry of Health's flagship public institution in Quito ; and a major Phase II–III research site across infectious disease, oncology, gastroenterology, neurology, and internal medicine; affiliated with the Universidad Central del Ecuador Faculty of Medical Sciences, which produces the primary investigator pipeline for Quito's public hospital research network; Hospital Eugenio Espejo's patient catchment from across Quito's diverse metropolitan population ; encompassing highland mestizo, Kichwa-speaking indigenous migrants, and Afro-Ecuadorian communities in the northern suburbs ; creates research access to the full demographic diversity of Ecuador's Andean urban population; neurology departments managing neurocysticercosis and other altitude-region neurological conditions make this site particularly relevant for anti-helminthic and CNS clinical programs targeting highland Ecuador's NCC burden. |
| 08 | Hospital Metropolitano | Quito | Quito's most internationally oriented private hospital ; a comprehensive private medical centre in the northern residential district of Quito serving Ecuador's professional and expatriate communities ; and an active Phase II–IV commercial research site across oncology, cardiovascular, metabolic disease, and internal medicine; Hospital Metropolitano's research department maintains established commercial pharmaceutical company partnerships and operates to GCP documentation standards reflecting its international patient community's expectations of US and European clinical standard equivalence; its patient catchment from Quito's professional and diplomatic community ; including Ecuador's largest concentration of foreign residents ; creates a demographically distinctive research population at 2,850m altitude. |
| 09 | Hospital Voz Andes (HCJB Global) | Quito | An internationally connected mission hospital in Quito operated by HCJB Global ; a Christian humanitarian organisation that has maintained health and research programmes in Ecuador since 1955 ; with Phase II–III research activity in infectious disease, tropical medicine, and community health; Hospital Voz Andes' long-standing relationship with North American and European medical missionary communities has created an institutional research culture with strong English-language documentation capability, established international academic partnerships, and experience in community-level tropical disease research programs extending beyond Quito into the sub-Andean foothills and Amazonian transition zones where leishmaniasis and other tropical NTDs are endemic; a distinctive private mission hospital research environment whose community research reach extends beyond the metropolitan hospital setting. |
| 10 | Hospital Pablo Arturo Suárez | Quito | A major MSP public hospital in northern Quito ; one of the most important public general hospitals in the highland Andean corridor ; with Phase II–III research activity across respiratory disease, infectious disease, internal medicine, and oncology; Hospital Pablo Arturo Suárez's northern Quito location provides research access to Ecuador's large highland indigenous and migrant mestizo population in one of the metropolitan area's most densely populated districts; its respiratory disease department ; managing a high-altitude COPD and bronchitis burden that reflects the combined effect of altitude, cooking smoke exposure in indigenous communities, and Ecuador's historically high TB burden in Andean provinces ; creates specific respiratory research opportunities relevant to highland-specific respiratory disease programs. |
| 11 | Hospital Vicente Corral Moscoso | Cuenca | The primary MSP public reference hospital for southern Ecuador ; located in Cuenca, Ecuador's third city (~650,000) and the capital of Azuay Province in the southern Andes at approximately 2,530m altitude ; affiliated with the Universidad de Cuenca Faculty of Medicine and serving as the regional health anchor for the provinces of Azuay, Cañar, and Morona Santiago; Phase II–III across oncology, cardiovascular, gastroenterology (gastric cancer and H. pylori research reflecting the elevated rates in the southern Andean population), and internal medicine; Hospital Vicente Corral Moscoso's position in Ecuador's most historically European-influenced highland city ; Cuenca is a UNESCO World Heritage site with a significant mestizo population of primarily Spanish and Andean ancestry ; provides a demographically distinct Andean research catchment complementary to Quito's larger metropolitan population. |
| 12 | Hospital José Carrasco Arteaga (IESS Cuenca) | Cuenca | IESS's flagship hospital in southern Ecuador ; the formal sector insurance coverage anchor for Azuay Province and Ecuador's southern highlands ; with Phase II–III research activity across cardiovascular, metabolic disease, and internal medicine; Hospital José Carrasco Arteaga's IESS managed care patient base provides structured research access to Cuenca's formal sector worker population ; a predominantly mestizo middle-class demographic with the structured healthcare engagement patterns that characterise IESS insurance systems across Ecuador ; providing an important institutional complement to Hospital Vicente Corral Moscoso's MSP public patient catchment for sponsors designing complete southern highland Phase III site coverage; the Cuenca dual-hospital model (IESS + MSP) mirrors the Guayaquil and Quito dual-system patterns that define Ecuador's healthcare architecture. |
One of South America's most historically significant hospitals ; operated since 1896 by the Junta de Beneficencia de Guayaquil, a private charitable foundation whose century-long hospital management tradition has created Ecuador's most institutionally stable major hospital outside the public sector ; and Guayaquil's most research-active institution; Phase I–IV across infectious disease, cardiovascular, oncology, gastroenterology, and internal medicine; Hospital Luis Vernaza's position as Ecuador's Pacific coast reference hospital for complex medicine and its long international reputation attract the most experienced Guayaquil investigator community and the most established pharmaceutical company relationships of any coastal Ecuadorian research institution; an essential first-call site for sponsors activating Guayaquil as the anchor of Ecuador Pacific corridor Phase II–III programs.
IESS's flagship hospital on Ecuador's Pacific coast ; one of the largest and most sophisticated public hospitals in coastal South America ; covering IESS-insured formal sector workers and their families across Guayaquil and the Pacific coastal provinces; Phase II–IV across cardiovascular, oncology, metabolic disease, haematology, infectious disease, and internal medicine; Hospital Maldonado Carbo's massive patient volume ; managing hundreds of thousands of consultations across IESS's managed care infrastructure ; provides structured research access to Guayaquil's large mestizo and Afro-Ecuadorian working-class patient population through the formal insurance system; a critical site for sponsors requiring IESS patient-base access in Pacific coast Phase III designs where enrollment velocity is a primary driver of site selection.
A major MSP public referral hospital in Guayaquil ; one of the highest-volume public general hospitals on the Ecuadorian coast ; with Phase II–III research activity across infectious disease (dengue being the most clinically relevant given Guayaquil's hyperendemic status), oncology, cardiovascular, and internal medicine; Hospital Abel Gilbert Pontón's catchment from Guayaquil's lower-income urban and peri-urban districts provides research access to the large treatment-naïve patient populations most relevant to dengue, tropical disease, and metabolic disease programs; an important MSP complement to the IESS and private hospital research networks for sponsors requiring broad Guayaquil public patient coverage.
Guayaquil's most internationally connected private hospital group ; operating multiple campuses across Guayaquil's residential and commercial districts ; and the most sophisticated private research institution in coastal Ecuador; Phase II–IV across oncology, cardiovascular, metabolic disease, and internal medicine; Clínica Kennedy's patient catchment from Guayaquil's professional and upper-middle-income population provides access to a private-pay mestizo and White Ecuadorian demographic whose health literacy and trial compliance rates are comparable to private research hospital populations in larger LATAM markets such as Bogotá or Lima; an important private hospital complement for sponsors designing Ecuador multi-site Phase III programs requiring patient coverage across the full Guayaquil socioeconomic spectrum.
IESS's dedicated paediatric hospital in Guayaquil ; Ecuador's most important site for paediatric clinical research on the Pacific coast ; with Phase II–III activity across paediatric infectious disease (dengue in children, a critical population for dengue vaccine immunogenicity Phase II studies given the age-stratified immunological responses to dengue infection), respiratory disease, haematology, and paediatric oncology; Hospital Roberto Gilbert's paediatric infectious disease department has been active in dengue-related clinical programs reflecting Guayaquil's hyperendemic transmission environment, where paediatric dengue burden and age-specific seroprevalence patterns create important trial design opportunities for sponsors developing dengue vaccines requiring age-stratified immunogenicity data in a hyperendemic setting.
Ecuador's largest and most sophisticated public tertiary hospital ; IESS's flagship in the Andean highlands, located in Quito at 2,850m above sea level ; and the most research-active institution in highland Ecuador; Phase I–IV across cardiovascular, oncology, metabolic disease, haematology, neurology, and endocrinology; HECAM's extraordinary concentration of specialty medical expertise and diagnostic infrastructure ; reflecting its role as IESS's national reference hospital for complex medicine ; makes it the primary Phase II–III trial site for high-complexity cardiovascular, oncology, and haematological malignancy programs in highland Ecuador; its altitude-adapted Andean patient population provides unique pharmacokinetic research value for sponsors whose drugs require altitude-stratified data within a Latin American regulatory submission.
Ecuador's national MSP referral hospital ; the Ministry of Health's flagship public institution in Quito ; and a major Phase II–III research site across infectious disease, oncology, gastroenterology, neurology, and internal medicine; affiliated with the Universidad Central del Ecuador Faculty of Medical Sciences, which produces the primary investigator pipeline for Quito's public hospital research network; Hospital Eugenio Espejo's patient catchment from across Quito's diverse metropolitan population ; encompassing highland mestizo, Kichwa-speaking indigenous migrants, and Afro-Ecuadorian communities in the northern suburbs ; creates research access to the full demographic diversity of Ecuador's Andean urban population; neurology departments managing neurocysticercosis and other altitude-region neurological conditions make this site particularly relevant for anti-helminthic and CNS clinical programs targeting highland Ecuador's NCC burden.
Quito's most internationally oriented private hospital ; a comprehensive private medical centre in the northern residential district of Quito serving Ecuador's professional and expatriate communities ; and an active Phase II–IV commercial research site across oncology, cardiovascular, metabolic disease, and internal medicine; Hospital Metropolitano's research department maintains established commercial pharmaceutical company partnerships and operates to GCP documentation standards reflecting its international patient community's expectations of US and European clinical standard equivalence; its patient catchment from Quito's professional and diplomatic community ; including Ecuador's largest concentration of foreign residents ; creates a demographically distinctive research population at 2,850m altitude.
An internationally connected mission hospital in Quito operated by HCJB Global ; a Christian humanitarian organisation that has maintained health and research programmes in Ecuador since 1955 ; with Phase II–III research activity in infectious disease, tropical medicine, and community health; Hospital Voz Andes' long-standing relationship with North American and European medical missionary communities has created an institutional research culture with strong English-language documentation capability, established international academic partnerships, and experience in community-level tropical disease research programs extending beyond Quito into the sub-Andean foothills and Amazonian transition zones where leishmaniasis and other tropical NTDs are endemic; a distinctive private mission hospital research environment whose community research reach extends beyond the metropolitan hospital setting.
A major MSP public hospital in northern Quito ; one of the most important public general hospitals in the highland Andean corridor ; with Phase II–III research activity across respiratory disease, infectious disease, internal medicine, and oncology; Hospital Pablo Arturo Suárez's northern Quito location provides research access to Ecuador's large highland indigenous and migrant mestizo population in one of the metropolitan area's most densely populated districts; its respiratory disease department ; managing a high-altitude COPD and bronchitis burden that reflects the combined effect of altitude, cooking smoke exposure in indigenous communities, and Ecuador's historically high TB burden in Andean provinces ; creates specific respiratory research opportunities relevant to highland-specific respiratory disease programs.
The primary MSP public reference hospital for southern Ecuador ; located in Cuenca, Ecuador's third city (~650,000) and the capital of Azuay Province in the southern Andes at approximately 2,530m altitude ; affiliated with the Universidad de Cuenca Faculty of Medicine and serving as the regional health anchor for the provinces of Azuay, Cañar, and Morona Santiago; Phase II–III across oncology, cardiovascular, gastroenterology (gastric cancer and H. pylori research reflecting the elevated rates in the southern Andean population), and internal medicine; Hospital Vicente Corral Moscoso's position in Ecuador's most historically European-influenced highland city ; Cuenca is a UNESCO World Heritage site with a significant mestizo population of primarily Spanish and Andean ancestry ; provides a demographically distinct Andean research catchment complementary to Quito's larger metropolitan population.
IESS's flagship hospital in southern Ecuador ; the formal sector insurance coverage anchor for Azuay Province and Ecuador's southern highlands ; with Phase II–III research activity across cardiovascular, metabolic disease, and internal medicine; Hospital José Carrasco Arteaga's IESS managed care patient base provides structured research access to Cuenca's formal sector worker population ; a predominantly mestizo middle-class demographic with the structured healthcare engagement patterns that characterise IESS insurance systems across Ecuador ; providing an important institutional complement to Hospital Vicente Corral Moscoso's MSP public patient catchment for sponsors designing complete southern highland Phase III site coverage; the Cuenca dual-hospital model (IESS + MSP) mirrors the Guayaquil and Quito dual-system patterns that define Ecuador's healthcare architecture.
These are the primary regulatory, academic, and industry bodies shaping Ecuador's clinical research ecosystem.
Ecuador's national health regulatory authority under the Ministerio de Salud Pública ; the competent authority for clinical trial authorisation, pharmaceutical product registration, and health technology assessment; ARCSA's clinical trial regulatory framework under Acuerdo Ministerial 5009 and subsequent resolutions incorporates WHO GCP and ICH GCP E6(R2) principles; its regulatory engagement with the CAN pharmaceutical harmonisation framework aligns Ecuador's standards progressively with Colombia and Peru, creating a natural multi-country regulatory context for Andean corridor Phase III programs.
Ecuador's Ministry of Public Health ; overseeing the national public hospital network (Hospital Eugenio Espejo, Hospital Abel Gilbert Pontón, Hospital Pablo Arturo Suárez, regional hospitals, and district health centres across all four ecological zones) and coordinating the national clinical research ethics framework through the network of institutional CEIs; the MSP's INSPI coordinates Ecuador's WHO-partnered infectious disease epidemiological surveillance providing the dengue, malaria, and tropical disease incidence data underpinning commercial tropical disease trial feasibility assessments across Ecuador's four geographic corridors.
Ecuador's national science, technology, and innovation secretariat ; the government body funding competitive biomedical and health research through grants to Ecuadorian universities and research institutes; SENESCYT's research funding programmes support infectious disease, tropical medicine, and pharmacogenomics research at the Universidad Central del Ecuador, Universidad de Guayaquil, USFQ, and INSPI; its international academic cooperation agreements facilitate the cross-border investigator partnerships through which multinational Phase II–III commercial programmes activate Ecuadorian sites within global trial networks.
Ecuador's national public health research institute ; headquartered in Guayaquil and operating regional laboratories across all four of Ecuador's geographic zones ; functioning as a WHO reference laboratory for selected tropical diseases and as the primary coordinating body for Ecuador's infectious disease epidemiological surveillance; INSPI's regional diagnostic and research laboratories provide dengue serotyping, malaria parasite characterisation, leishmaniasis diagnostic, and emerging pathogen surveillance capabilities that underpin Ecuador's tropical disease clinical research infrastructure.
Ecuador's most internationally connected private university ; modelled on a US liberal arts university, accredited by WASC Senior College and University Commission, and maintaining active research partnerships with US, European, and Latin American academic institutions ; whose College of Health Sciences and Institute for Microbiology conduct internationally published research in infectious disease, tropical medicine, molecular biology, and pharmacogenomics; USFQ's investigator community is among Ecuador's most internationally oriented.
Ecuador's primary public university and the academic anchor of Quito's public hospital research network ; affiliated with Hospital Eugenio Espejo, Hospital Pablo Arturo Suárez, and other MSP teaching hospitals in the highland corridor ; producing the national investigator pipeline for Andean Ecuador's public health system research; the Faculty of Medical Sciences maintains active research programmes in tropical infectious disease, cardiovascular medicine, and neurology.
Ecuador's largest public university by enrolment and the academic anchor of coastal Ecuador's public hospital research network ; affiliated with Hospital Luis Vernaza, Hospital Abel Gilbert Pontón, and other MSP and Junta de Beneficencia teaching hospitals in the coastal corridor ; producing the physician investigator community that staffs commercial trial activity across Guayaquil's public hospital network; institutional source of Ecuador's most significant dengue and coastal infectious disease clinical research publications.
Global CRO with Ecuadorian operations managing Phase II–IV programs across tropical and infectious disease, oncology, cardiovascular, and metabolic disease indications; ARCSA regulatory submission expertise and institutional CEI ethics application support across Guayaquil and Quito; established site monitoring networks across Hospital Luis Vernaza, HECAM, Hospital Eugenio Espejo, Clínica Kennedy, and the IESS hospital networks in both corridors; USD-denominated financial operations providing budget stability.
International CRO with Ecuadorian operations supporting Phase II–IV infectious disease, oncology, and cardiovascular programs; established investigator relationships across Ecuador's dual Guayaquil and Quito research corridors; specialist dengue and tropical disease trial management reflecting Ecuador's Pacific coast hyperendemic profile; ARCSA regulatory strategy for sponsors using Ecuador as the Andean tropical disease anchor of regional Phase II–III programs.
Global CRO with Ecuadorian operations providing Phase II–III trial management and ARCSA regulatory strategy across tropical disease, oncology, cardiovascular, and metabolic disease indications; established site networks across Guayaquil's Hospital Luis Vernaza, Clínica Kennedy, and IESS coastal hospitals alongside Quito's HECAM, Hospital Metropolitano, and USFQ academic networks; biostatistics and data management for Ecuador-site trials with multi-ancestry sub-group analysis.
International biopharmaceutical solutions company with Ecuadorian operations providing integrated Phase I–IV clinical development services across tropical infectious disease, cardiovascular, oncology, and metabolic disease; ARCSA submission expertise and institutional CEI ethics navigation across both Guayaquil and Quito research corridors; USD-denominated budget management offering financial stability; regional Andean programme management coordinating Ecuador sites within Colombia-Peru-Bolivia integrated Phase III designs.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.